replimune.com
Get leads like Replimune — and thousands more
Build targeted lists by tech stack, traffic, and more
Replimune: Igniting the Cancer War
A commercial-stage biotech disrupting oncology with engineered viruses
In a field dominated by incremental improvements, Replimune is betting the house on a radical premise: using engineered viruses to systematically hunt down and destroy cancer. They're not just treating the disease; they're weaponizing biology itself.
"They aren't just innovating in the lab; they're building the infrastructure to bring a new class of drugs to market at scale."
The Oncolytic Edge
Replimune's platform (RP-1) uses a modified herpes simplex virus engineered to selectively replicate in tumor cells while leaving healthy tissue alone. This isn't gene therapy; it's 'virotherapy' designed to turn the immune system against cancer systemically. Their lead candidate, RP1, is in late-stage trials for melanoma and other solid tumors.
The Commercial Pivot
With revenue at $17.8M and 517 employees, Replimune has moved beyond pure R&D into commercial readiness. Their traffic profile—42% direct, 42% organic—suggests a highly targeted audience of investors, clinicians, and biotech professionals, not the general public. This is a B2B/B2G play, not a consumer brand.
The company's search volume reveals its true stakeholders. Keywords like 'replimune stock' (2,180 monthly searches) and 'replimune s-1' indicate intense investor scrutiny. Meanwhile, 'type a fda press release' searches show the market is watching for regulatory catalysts. This is a company priced on binary clinical readouts, not steady growth.
- RP-1 platform aims for 'abscopal effect'—treating distant metastases via systemic immune response
- Commercial-stage with $17.8M revenue implies early product launches or partnerships
- 517 employees suggest significant manufacturing and clinical trial infrastructure
- Backed by $87M in funding, positioning for Phase 3 trials and potential commercialization
The High-Stakes Bet
Replimune represents the convergence of biotech innovation and commercial readiness. With $17.8M in revenue and 517 employees, they're past the 'idea' phase and into execution. The question isn't if oncolytic immunotherapy works—it's whether Replimune can scale it profitably while navigating FDA approval.
What tech stack does Replimune use?
How much traffic does Replimune get?
Traffic & Engagement
Traffic Sources
Where is Replimune's audience located?
What keywords does Replimune rank for?
5 keywordsHow is Replimune's SEO?
Open Graph Image
https://replimune-group.transforms.svdcdn.com/production/general/meta.jpg?w=1200&h=630&q=82&auto=format%2Cavif&fit=crop&dm=1748532973&s=bd5ab0c45e847b1fec811a0378671566
Meta Tags
Oncolytic Immunotherapies | Replimune
Replimune is a commercial-stage biotech company revolutionizing cancer treatment with a new class of oncolytic immunotherapies designed to activate a…
Oncolytic Immunotherapies
H1 Tags
Schema Types
What is Replimune's revenue?
Who works at Replimune?
Loading leads...
What do customers think of Replimune?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Replimune
What is Replimune's Revenue?
What does Replimune do?
How fast is Replimune growing?
What technologies does Replimune use?
Who are Replimune's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Replimune?
Export replimune.com Data
Download the complete tech stack, analytics, leads, and company data for replimune.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About replimune.com
Replimune is a commercial-stage biotech company revolutionizing cancer treatment with a new class of oncolytic immunotherapies designed to activate a…
Company Overview
replimune.com Social Media
Contact replimune.com
Email Addresses
Phone Numbers
Technology Stack
replimune.com uses 8 technologies across their website including HSTS, Cloudflare, OneTrust, and more.
Security
HSTS
Cloud & Hosting
Cloudflare
Privacy & Consent
OneTrust
Analytics & Marketing
Google Analytics
Performance
Priority Hints
Web Standards
Twitter Cards
Traffic & Audience
replimune.com receives approximately 8.3K monthly visitors and ranks #2,770,489 globally. The website has a bounce rate of 54% with visitors viewing an average of 1.4 pages per visit. Users spend an average of 0:04 on the site.
The majority of replimune.com's traffic comes from undefined, undefined, .
Frequently Asked Questions
What is replimune.com?
What technologies does replimune.com use?
How do I contact replimune.com?
What are replimune.com's social media accounts?
Is replimune.com hiring?
How popular is replimune.com?
Related Searches
This page provides publicly available information about replimune.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit replimune.com directly at https://replimune.com.